Cinacalcet Mylan

Nchi: Umoja wa Ulaya

Lugha: Kiingereza

Chanzo: EMA (European Medicines Agency)

Nunua Sasa

Taarifa za kipeperushi Taarifa za kipeperushi (PIL)
20-03-2024
Tabia za bidhaa Tabia za bidhaa (SPC)
20-03-2024

Viambatanisho vya kazi:

cinacalcet hydrochloride

Inapatikana kutoka:

Mylan Pharmaceuticals Limited

ATC kanuni:

H05BX01

INN (Jina la Kimataifa):

cinacalcet

Kundi la matibabu:

Calcium homeostasis

Eneo la matibabu:

Hyperparathyroidism, Secondary; Hypercalcemia

Matibabu dalili:

Treatment of secondary hyperparathyroidism (HPT) in patients with end-stage renal disease (ESRD) on maintenance dialysis therapy.Cinacalcet Mylan may be used as part of a therapeutic regimen including phosphate binders and/or vitamin D sterols, as appropriate.Reduction of hypercalcaemia in patients with:parathyroid carcinomaprimary HPT for whom parathyroidectomywould be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated. 

Bidhaa muhtasari:

Revision: 15

Idhini hali ya:

Authorised

Idhini ya tarehe:

2015-11-19

Taarifa za kipeperushi

                                38
B. PACKAGE LEAFLET
39
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
CINACALCET MYLAN 30 MG FILM-COATED TABLETS
CINACALCET MYLAN 60 MG FILM-COATED TABLETS
CINACALCET MYLAN 90 MG FILM-COATED TABLETS
cinacalcet
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Cinacalcet Mylan is and what it is used for
2.
What you need to know before you take Cinacalcet Mylan
3.
How to take Cinacalcet Mylan
4.
Possible side effects
5.
How to store Cinacalcet Mylan
6.
Contents of the pack and other information
1.
WHAT CINACALCET MYLAN IS AND WHAT IT IS USED FOR
Cinacalcet Mylan contains the active ingredient cinacalcet, which
works by controlling the levels of
parathyroid hormone (PTH), calcium and phosphorous in your body. It is
used to treat problems with
organs called parathyroid glands. The parathyroids are four small
glands in the neck, near the thyroid
gland, that produce parathyroid hormone (PTH).
Cinacalcet Mylan is used in adults:
•
to treat secondary hyperparathyroidism in adults with serious kidney
disease who need dialysis
to clear their blood of waste products
•
to reduce high levels of calcium in the blood (hypercalcaemia) in
adult patients with parathyroid
cancer
•
to reduce high levels of calcium in the blood (hypercalcaemia) in
adult patients with primary
hyperparathyroidism when removal of the parathyroid gland is not
possible.
Cinacalcet Mylan is used in children aged 3 years to less than 18
years of age:
•
to treat secondary hyperparathyroidism in patients with serious kidn
                                
                                Soma hati kamili
                                
                            

Tabia za bidhaa

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Cinacalcet Mylan 30 mg film-coated tablets.
Cinacalcet Mylan 60 mg film-coated tablets.
Cinacalcet Mylan 90 mg film-coated tablets.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Cinacalcet Mylan 30 mg film-coated tablets
Each film-coated tablet contains 30 mg of cinacalcet (as
hydrochloride).
Cinacalcet Mylan 60 mg film-coated tablets
Each film-coated tablet contains 60 mg of cinacalcet (as
hydrochloride).
Cinacalcet Mylan 90 mg film-coated tablets
Each film-coated tablet contains 90 mg of cinacalcet (as
hydrochloride).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
Cinacalcet Mylan 30 mg film-coated tablets
10.0 mm x 6.4 mm, green, film-coated, oval, biconvex, bevelled edge
tablet debossed with M on one
side of the tablet and CI30 on the other side.
Cinacalcet Mylan 60 mg film-coated tablets
12.5 mm x 8.0 mm, green, film-coated, oval, biconvex, bevelled edge
tablet debossed with M on one
side of the tablet and CI60 on the other side.
Cinacalcet Mylan 90 mg film-coated tablets
14.3 mm x 9.0 mm, green, film-coated, oval, biconvex, bevelled edge
tablet debossed with M on one
side of the tablet and CI90 on the other side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Secondary hyperparathyroidism
_Adults _
Treatment of secondary hyperparathyroidism (HPT) in adult patients
with end-stage renal disease
(ESRD) on maintenance dialysis therapy.
3
_Paediatric population _
Treatment of secondary hyperparathyroidism (HPT) in children aged 3
years and older with end-stage
renal disease (ESRD) on maintenance dialysis therapy in whom secondary
HPT is not adequately
controlled with standard of care therapy (see section 4.4).
Cinacalcet Mylan may be used as part of a therapeutic regimen
including phosphate binders and/or
vitamin D sterols, as appropriate (see section 5.1).
Parathyroid carcinoma and primary hyperparathyroidism in adults
Reduction of hypercalcaemia in adult patients with:
•
parathyroi
                                
                                Soma hati kamili
                                
                            

Nyaraka katika lugha zingine

Taarifa za kipeperushi Taarifa za kipeperushi Kibulgaria 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kibulgaria 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kibulgaria 27-11-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kihispania 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kihispania 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihispania 27-11-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kicheki 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kicheki 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kicheki 27-11-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kidenmaki 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kidenmaki 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kidenmaki 27-11-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kijerumani 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kijerumani 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kijerumani 27-11-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kiestonia 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kiestonia 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiestonia 27-11-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kigiriki 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kigiriki 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kigiriki 27-11-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kifaransa 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kifaransa 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifaransa 27-11-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kiitaliano 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kiitaliano 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiitaliano 27-11-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kilatvia 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kilatvia 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilatvia 27-11-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kilithuania 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kilithuania 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilithuania 27-11-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kihungari 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kihungari 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihungari 27-11-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kimalta 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kimalta 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kimalta 27-11-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kiholanzi 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kiholanzi 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiholanzi 27-11-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kipolandi 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kipolandi 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kipolandi 27-11-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kireno 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kireno 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kireno 27-11-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kiromania 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kiromania 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiromania 27-11-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kislovakia 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kislovakia 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovakia 27-11-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kislovenia 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kislovenia 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovenia 27-11-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kifinlandi 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kifinlandi 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifinlandi 27-11-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kiswidi 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kiswidi 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiswidi 27-11-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kinorwe 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kinorwe 20-03-2024
Taarifa za kipeperushi Taarifa za kipeperushi Kiaisilandi 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kiaisilandi 20-03-2024
Taarifa za kipeperushi Taarifa za kipeperushi Kroeshia 20-03-2024
Tabia za bidhaa Tabia za bidhaa Kroeshia 20-03-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kroeshia 27-11-2015

Tafuta arifu zinazohusiana na bidhaa hii